Mutations in fukutin-related protein (FKRP) cause a common subset of muscular dystrophies characterized by aberrant glycosylation of alpha-dystroglycan (a-DG), collectively known as dystroglycanopathies. The clinical variations associated with FKRP mutations range from mild limb-girdle muscular dystrophy type 2I with predominantly muscle phenotypes to severe Walker -Warburg syndrome and muscle -eye -brain disease with striking structural brain and eye defects. In the present study, we have generated animal models and demonstrated that ablation of FKRP functions is embryonic lethal and that the homozygous-null embryos die before reaching E12.5. The homozygous knock-in mouse carrying the missense P448L mutation almost completely lacks functional glycosylation of a-DG in muscles and brain, validating the essential role of FKRP in the functional glycosylation of a-DG. However, the knock-in mouse survives and develops a wide range of structural abnormalities in the central nervous system, characteristics of neuronal migration defects. The brain and eye defects are highly reminiscent of the phenotypes seen in severe dystroglycanopathy patients. In addition, skeletal muscles develop progressive muscular dystrophy. Our results confirm that post-translational modifications of a-DG are essential for normal development of the brain and eyes. In addition, both the mutation itself and the levels of FKRP expression are equally critical for the survival of the animals. The exceptionally wide clinical spectrums recapitulated in the P448L mice also suggest the involvement of other factors in the disease progression. The mutant mouse represents a valuable model to further elucidate the functions of FKRP and develop therapies for FKRP-related muscular dystrophies.
INTRODUCTION
The dystrophin -glycoprotein complex (DGC) at the sarcolemma provides a physical linkage between the actin cytoskeleton and the extracellular matrix (ECM) that is crucial for the maintenance of muscle membrane stability (1, 2) . It is well established that disruption of this linkage causes different forms of muscular dystrophies (3) . Dystroglycan (DG) is an essential component of the DGC (4, 5) . The polypeptide is posttranslationally cleaved into two closely associated subunits of DG: a-DG and b-DG (6) . a-DG is extensively glycosylated with both N-and O-linked glycans and acts as a cellular receptor for laminin and other ECM proteins, including agrin, perlecan, neurexin and pikachurin (7 -13) . The function of a-DG and its interaction with ECM proteins largely depend on O-linked glycosylation in the mucin-like domain (central region) of the polypeptide (2, 14, 15) . Although DG was originally characterized in skeletal and cardiac muscles, it also plays an important role in the development of the brain, eye and peripheral nerves (16) (17) (18) (19) (20) .
Recently, a subset of muscular dystrophies, known as dystroglycanopathies, has been characterized by a common secondary defect in DG glycosylation. The defect is the result of autosomal-recessive mutations in at least six different genes (21) . Examples of these include fukutin-related protein (FKRP), fukutin, LARGE, POMGnT1, POMT1 and POMT2. A number of studies have suggested that these genes are involved in post-translational modifications of a-DG (22) (23) (24) (25) (26) (27) (28) . POMT1, POMT2 and POMGnT1 were shown to initiate the first two steps of the O-mannosylation pathway, a unique type of O-linked glycosylation in a-DG (25, 29) . There is also evidence to support LARGE being a glycosyltransferase (30) (31) (32) . In contrast, the functions of FKRP are largely unknown. Although mutations in the gene are associated with hypoglycosylation of a-DG, there is no biochemical data to support its direct involvement in a-DG modifications (33) .
The clinical spectra of dystroglycanopathies can vary considerably. The severe end of the spectrum consists of Walker -Warburg syndrome (WWS) caused by mutations in the POMT1 and POMT2 genes, muscle -eye -brain (MEB) disease caused by mutations in the POMGnT1 gene and Fukuyama congenital muscular dystrophy caused by mutations in the fukutin gene. These disorders show significant defects, including distinctive structural changes in the brain (cobblestone type II lissencephaly) and eye (retinal hypoplasia), in the central nervous system (CNS) and frequently result in early lethality. Mutations in some of the dystroglycanopathy genes are often associated with variable clinical severity. In particular, genetic defects in FKRP have been reported to cause clinically distinct diseases from WWS and MEB to less severe congenital muscular dystrophies (MDC1C) with or without CNS involvement and mild limbgirdle muscular dystrophy type 2I (LGMD2I) with predominantly myopathic phenotypes (34) (35) (36) . Cardiomyopathy is also observed in some LGMD2I patients (37, 38) . Recent studies of FKRP-related muscular dystrophies have not been able to establish a clear genotype -phenotype correlation to account for these variations (39) . In addition, the levels of a-DG glycosylation determined by immunostaining of muscle biopsies were shown to vary in patients (39, 40) . Furthermore, a recent study has reported that a knock-in mouse model with a homozygous missense Y307N mutation [together with a neomycin-resistance (Neo r ) cassette] in the FKRP gene expresses relatively abundant functional a-DG, but the animals died at or soon after birth, raising the question of whether FKRP is essential for functional glycosylation of a-DG and the possibility that other factors might also influence disease severity (41) .
In this study, we generated two mouse models using both knock-in and knockout technologies to investigate the functional roles of FKRP in muscular dystrophies. First, we engineered a missense P448L mutation in the mouse Fkrp gene. This mutation was previously associated with MDC1C (28, 36) and shown to affect the localization of the FKRP protein (42, 43) . The homozygous knock-in mice are viable and recapitulate the variable clinical phenotypes of FKRP-associated muscular dystrophies. Besides the dystrophic pathology in skeletal muscles, the mutant animals also develop striking abnormalities in the brain and eyes, associated with severe forms of dystroglycanopathies. Biochemical analysis showed that a-DG is not functionally glycosylated as determined by the loss of its glyco-epitope and laminin-binding capability. On the other hand, deletion of the C-terminal consensus DxD motif in FKRP resulted in early embryonic lethality. Together, our findings clearly demonstrate an important role of FKRP during both embryonic and post-embryonic development of muscles and CNS. The abnormalities observed in the mutant mice support the current hypothesis that FKRP is essential for the functional modifications of a-DG. However, the significant upregulation of b 1 -integrin in the mutant muscles suggests that other factors may also be responsible for the wide variation in disease severity. The homozygous P448L mice are highly valuable not only for elucidating the disease mechanism and progression in long-term studies, but also for developing therapeutic strategies for FKRP-related muscular dystrophies in the future.
RESULTS

Generation of FKRP knock-in and deletion mice
To generate the knock-in animal model, we designed a targeting vector containing a C1343T point mutation in the exon 3 of the mouse Fkrp gene. The resulting missense mutation changed the amino acid at the position 448 from proline to leucine (P448L). The Neo r was inserted in the intron 2 and flanked by two loxP and FRT recognition sites (Fig. 1A -C) . Targeted ES cells were identified by polymerase chain reaction (PCR) and confirmed by Southern blots prior to injection to the blastocytes (Supplementary Material, Fig. S1A ). The entire coding region of FKRP of all positive ES clones was sequenced to confirm the P448L mutation. Germlinetransmitted heterozygous mice were obtained and cross-bred to generate homozygous FKRP knock-in mice (referred to as FKRP-neo-P448L/FKRP-neo-P448L or FKRP-neo-P448L mutant mice hereafter). The genotype of the mice was identified by allele-specific PCR primers that can distinguish the wild-type from the targeted FKRP alleles (Supplementary Material, Fig. S1B ). Integration of the targeting vector to the FKRP locus was re-confirmed by PCR, using one primer matching the genomic sequence not included in the targeting vector and the other matching the Neo r sequence (Supplementary Material, Fig. S1C ). The engineered P448L mutation was further confirmed by genomic DNA sequencing. As several studies have recently shown that both FKRP and sarcoglycan knock-in mouse models did not develop phenotypes after removal of the Neo r cassette, we have decided to retain the Neo r cassette in the targeted FKRP alleles (41, 44, 45) . FKRP deletion mice were generated by removing the FKRP coding sequence from amino acid E310 to the TGA stop codon in the targeting vector ( Fig. 1D-E) . The C terminus of FKRP contains a consensus DxD motif commonly found in other glycosyltransferases. As this motif is generally thought to be critical for the function of proteins, we expect that the deletion of the C-terminal end of FKRP would lead to loss of the protein function. The functional knockout homozygote is referred to as E310del/E310del.
FKRP-null mice are embryonic lethal
Heterozygous E310del/wt mice were fertile and phenotypically normal as judged by visual examination and muscle histology. Western blot analysis demonstrated that the levels of functional glycosylation of a-DG in the heterozygous muscles were similar to that of wild-type muscles (data not shown). However, we were not able to obtain homozygous mutants from cross-breeding of heterozygous mice ( 
Phenotypes of homozygous FKRP-neo-P448L knock-in mice
Heterozygous FKRP-neo-P448L/wt mice showed no obvious physical or behavioral abnormalities when compared with wildtype mice. The number of FKRP-neo-P448L homozygous mutant mice born from mating of heterozygous parents roughly followed the Mendelian ratio (Table 1, P448L/ P448L). However, approximately one-third of the mutant mice died at birth or within 2 days. The remaining animals survived beyond 6 months. The mutant mice were visibly smaller than their wild-type and heterozygous siblings at birth and remained 20% smaller by weight (P ¼ 0.0002) throughout adulthood ( Fig. 2A and Supplementary Material, Fig. S2 ). Muscle weakness became evident in the mutant mice as early as 2 weeks and was demonstrated by the abnormal retracting position of the hind limbs when the mice were suspended by the tails (Fig. 2B and C) . The dystrophic phenotypes in muscles were consistent with elevated serum creatine kinase (CK) levels in the mutant mice and 10 times (8260 units/l, P ¼ 0.0024) higher than the wild-type controls (770 units/l; Supplementary Material, Fig. S3 ). The levels of alanine transaminase (ALT) were also significantly higher in the mutant mice. The results of blood urea nitrogen (BUN), alkaline phos- phatase (ALP) and cholesterol tests did not reveal major differences between the mutant and wild-type littermates. The other noticeable physical abnormality in more than half of the mutant mice was cranial deformation associated with enlarged skull and outward bulging of parietal bone ( Fig. 2D and E).
Complete examination of the brains revealed the formation of expanded lateral ventricles filled with cerebrospinal fluid, suggesting that the animals suffered from hydrocephalus.
Other skeleton bones appeared to be normal as judged by visual examination and X-ray. The FKRP-neo-P448L homozygous mutant mice also developed eye abnormalities by 3 -4 weeks old. The size of the two eyes varied ( Fig. 2F ) with a hazelike appearance in the affected eye, indicative of corneal opacification. The ocular and brain abnormality did not seem to progress further as the mice aged.
Levels of FKRP transcripts reduce in mutant mice and vary by tissues and ages
The presence of the Neo r cassette can affect the expression of the targeted gene and the disease severity/phenotype can be influenced by the level of gene expression (46) . As detection of endogenous FKRP protein is difficult to achieve (43), we performed quantitative real-time PCR to assess FKRP expression in the mutant animals using RNAs extracted from quadriceps, gastronemius and heart. The results showed that the levels of FKRP transcripts in the FKRP-neo-P448L mutant mice were reduced to 55% (P ¼ 0.02) compared with the wild-type controls (Fig. 2G , Supplementary Material, Fig. S4 ). On the other hand, the expression of other genes involved in dystroglycanopathies, such as fukutin, LARGE and dystroglycan, was not significantly changed in the mutant animals. Comparison of FKRP expression in different tissues revealed that the levels of FKRP mRNA in heart were 3-fold higher than those in skeletal muscles ( Fig. 2H , P , 0.005, Supplementary Material, Fig. S4 ). In addition, FKRP expression decreased significantly over time between 5 and 15 weeks in all three tissues examined ( Fig. 2I , P , 0.05). Al together, the expression data suggested that FKRP gene undergoes complex regulation during development and aging.
Dystrophic pathology in skeletal muscles of FKRP-neo-P448L mutant mice
The neonatal FKRP-neo-P448L mutant mice that died at birth or immediately after birth showed no obvious pathological changes in skeletal muscles, the heart and diaphragm (Supplementary Material, Fig. S5 ). However, when the mutant mice were examined at the age of 5 weeks and older, hallmark features characteristics of muscular dystrophies became evident in all skeletal muscles, including tibialis anterior, quadriceps, gastronemius, intercostals, biceps and diaphragm (Fig. 3A) . The pathological changes included variations in fiber sizes and presence of groups of necrotic fibers (stars) and central nuclei (arrow), indicating muscle degeneration and regeneration. These features of degeneration and regeneration were seen in nearly all cross-sections of muscles, but we also found focal areas with fibers of relatively normal size and without internalized nuclei and necrosis. Infiltration of mononuclear cells (arrowhead) and increased interstitial space were observed clearly only in the areas with large number of necrotic fibers. Fibrosis was not obvious in muscles of mutant mice at the age of 5 weeks, but became apparent at the age of 10 weeks or older as demonstrated by Trichrome Relative FKRP expression in wild-type (wt, n ¼ 4), heterozygous (het, n ¼ 6) and homozygous FKRP-neo-P448L (P448L, n ¼ 6) mice by quantitative RT-PCR analysis. The number of mice analyzed is denoted by n. The levels of reduction in FKRP expression were nearly identical in quadriceps, gastronemius and heart and individual results obtained from each tissue were combined to reflect the overall changes in FKRP expression among the genotypes. Expression of FKRP in wild-type mice was normalized to 1. Statistically significant changes (P ¼ 0.02) are obtained only between wildtype and mutant mice. (H) FKRP expression in gastronemius, heart and quadriceps. All three genotypes showed an 3 -4-fold increase in FKRP expression in heart compared with skeletal muscles. Graph was tabulated from the combined results of wild-type and heterozygous mice, demonstrating the relatively higher levels of FKRP mRNA in heart (P , 0.005). Ten and six animals were analyzed for FKRP expression in gastronemius/heart and quadriceps, respectively (I) FKRP expression in muscle and heart of 5-15-week-old mice. Graph was tabulated from the combined results of wildtype (n ¼ 4) and heterozygous mice (n ¼ 6). Note that FKRP expression in both gastronemius and heart followed similar trend of reduction over time.
The combined data has a P-value of ,0.05. Error bars represent mean + SEM. Material, Fig. S6 ). Muscle fiber degeneration, inflammatory infiltration and increased fibrotic tissues were, in general, more pronounced in the diaphragm. In contrast, H&E and Trichrome staining did not reveal dystrophic phenotypes in the heart of the FKRP-neo-P448L mice up to 10 months of age (Fig. 3A) . Kidney and liver were unaffected as examined by histology and this was corroborated with normal serum levels of ALP and BUN ( Supplementary  Material, Fig. S3 ). No pathological changes were observed in muscles of the wild-type or heterozygous littermates.
staining (Supplementary
Ultrastructural analysis of quadriceps from the FKRPneo-P448L mutant mice showed enlarged mitochondria (Fig. 3B, stars) . This is consistent with previous reports that the presence of swollen mitochondria might represent a secondary response to muscle degeneration in other muscle diseases (47) . We also observed significant numbers of degenerating vacuoles, especially beneath the sarcolemma (Fig. 3B, stars) . In addition, the sarcolemma appeared to be less uniform in the mutant muscle fibers. Some areas along the sarcolemma were discontinuous and lacked the plasma membrane (arrow). Consistent with the elevated serum CK levels, the electron microscopic findings suggested an underlying defect in the muscle membrane of the FKRP-neo-P448L mice.
Loss of functional a-DG glycosylation in FKRP-neo-P448L mutant mice
In view of the proposed function of FKRP in a-DG glycosylation, we examined the muscle tissues of the FKRP-neo-P448L mutant mice with monoclonal IIH6C4 and VIA4-1 antibodies. These two antibodies detect undefined glyco-epitopes of a-DG. The epitope(s) also overlaps with the laminin-binding site on the a-DG protein (2) . Western blot analysis revealed an almost complete absence of IIH6C4 and VIA4-1 signals in both skeletal and cardiac muscles ( Fig. 4A and B) . The laminin-binding activity of a-DG was also nearly abolished in the mutant skeletal and cardiac muscles as demonstrated by laminin overlay assay ( Fig. 4A and D) . This was in contrast to the normal functional glycosylation of a-DG in the muscles of wild-type and heterozygote littermates. The steady-state levels of a-DG in the FKRP-neo-P448L mutant mice did not change compared with the wild-type and heterozygous controls as judged by two different anti-a-DG antibodies (a-DG and DAG-1) (Fig. 4A) . As both a-DG and b-DG are post-translationally cleaved from a single polypeptide, these results are consistent with the notion that FKRP primarily affects glycosylation of a-DG, but not the protein levels.
The lack of functional glycosylation of a-DG was confirmed by immunofluorescent studies. Immunolabeling with both IIH6C4 and VIA4-1 antibodies was absent in all muscles of the FKRP-neo-P448L mutant mice (Fig. 5 and Supplementary Material, Fig. S7 ). However, we did not observe a reduction of laminin a2 staining in the mutant muscles (Fig. 5) . Staining for b-DG and dystrophin was normal in the mutant muscles. Groups of fibers with strong signals covering the whole fiber cross-section were detected, indicating severe membrane leakage with circulating IgGs inside the degenerating fibers (Fig. 5, arrowhead) . This observation supports the finding of EM that the sarcolemmal structure is compromised in the mutant muscles.
Given the critical role of the DGC in muscular dystrophies, we also compared the expressions of dystrophin, dysferlin and dystrobrevin among the three genotypes and found no obvious changes in their protein levels (Fig. 4A) . On the other hand, we observed a dramatic upregulation (.10 folds) of b 1 -integrin in the skeletal muscles, but not in the heart of the mutant mice ( Fig. 4A and Supplementary  Material, Fig. S8 ). As laminin a2 expression was unaffected in the FKRP-neo-P448L mutant mice, the increased levels of b 1 -integrin could compensate for the lack of functional DGC as suggested by Kaufman and his colleagues (48) (49) (50) . Further, western blot analysis of brain extracts also demonstrated that a-DG was aberrantly glycosylated in the FKRP-neo-P448L mice (Fig. 4C) . The immunoreactivity of IIH6C4 and VIA4-1 antibodies and the laminin-binding activity were nearly absent in all mutant brains similar to that in muscles (Fig. 4E) .
FKRP-neo-P448L mutant mice display multiple developmental defects in the CNS
As dystroglycanopathy patients of severe phenotypes show distinct CNS abnormalities, we analyzed the brains of the FKRP-neo-P448L mutant mice. By visual examination, gross structural abnormalities were noted in the brains of the mutant mice ranging from newborn to 15 weeks old (Fig. 6A) . The surface of the mutant brains had a smoother appearance reminiscent of cobblestone type II lissencephaly (five out of six examined). The appearance of brainstem was abnormal and did not assume the typical elongated structure, which is in consistent with the MRI findings in severe dystroglycanopathy patients (51) . Hydrocephalus was also a common feature in the mutant mice (four out of six examined). Immunofluorescence images of wild-type (wt, left column), heterozygous (het, middle column) and FKRP-neo-P448L mutant muscle (right column). Tissues shown in the figure (across each row) were heart, quadriceps, and diaphragm taken from 12-week-old mice. Immunostaining with IIH6C4 antibody was completely absent in the mutant muscle. Arrowhead indicates the degenerating fibers stained with goat-anti-mouse Igs Alexa594. In contrary, labeling intensity for laminin a2 in the FKRP-neo-P448L mutant muscle was normal and uniform at the sarcolemma compared with the wildtype and heterozygous muscles. Small fibers and central nucleation (blue spots, DAPI staining) were clearly visible in the FKRP-neo-P448L mutant muscle. Bar, 50 mm.
Histological studies revealed characteristic signs of abnormal migration of neurons in the cerebral cortex of FKRP-neo-P448L mutant mice. The interhemispheric fissure was fused characteristic of human polymicrogyria (Fig. 6B,  arrowhead) . The lateral ventricles became expanded (stars), consistent with the presence of hydrocephalus. The cortical laminar structures were disorganized such that the boundary between molecular layers I (MLI) and MLII was consistently obscured in most of the mutant brains examined (Fig. 6C) although areas which appeared to have normal laminar organization also existed. All wild-type and heterozygous littermates displayed normal cytoarchitecture.
The structural defects in cerebellum were striking in the FKRP-neo-P448L mice (six examined) and consistent with neuronal migration defects (Fig. 6B) . The architecture of the cerebellar folia was highly distorted and partly fused (Fig. 6D) . Neurons from the granular layer frequently formed clusters at the sub-plial layers between two adjacent folia (arrow). This result is consistent with recent MRI studies, showing that this part of the brain is highly susceptible to the changes in FKRP-related muscular dystrophies (51) . The hippocampus appeared to be moderately affected in some older mutant mice. Portion of the dentate gyrus was duplicated and not folded properly into the typical V-shape layer as reported in other animal models ( Fig. 6E;52-54 ). However, normal hippocampal architecture was observed in three out of six mutant animals examined.
Histological analysis also demonstrated structural abnormalities in the eyes of the FKRP-neo-P448L mutant mice indicative of hypotrophy. The retina is typically organized into distinct layers but was disrupted in the mutant mice (Fig. 7A ). Both the outer nuclear layer (ONL) and inner nuclear layer (INL) were thinner in the mutant mice than those of the wild-type or heterozygote mice. The ganglion cell layer (GCL) and inner limiting membrane were disrupted in the presence of ectopic cells outside the membrane. The optic nerves were generally smaller in the mutant mice, and cellular components were clearly disorganized near the retina (Fig. 7B) .
DISCUSSION
One of the challenges to understand the role of FKRP in muscular dystrophies is the lack of appropriate mouse models. Here we report the generation of two FKRP mouse models. While the homozygous FKRP deletion mice cause embryonic lethality, the homozygous FKRP-neo-P448L mice are viable and develop muscle weakness and wasting soon after birth. Pathological findings are consistent with a severe progressive dystrophy. Biochemical and immunochemical analyses demonstrate a marked decrease in a-DG staining using glycan-specific IIH6C4 and VIA4-1 antibodies. The laminin-binding activity of a-DG is also reduced to barely detectable levels in both muscles and brain, indicating that a-DG is not functionally glycosylated. The integrity of the sarcolemma appears to be compromised as supported by elevated serum CK levels and ultrastructural studies. These results are consistent with a destabilized linkage due to the loss or reduced binding of a-DG to laminin in the ECM. Thus, our knock-in animal model confirms a critical role of FKRP in muscle survival and function and supports the current hypothesis that FKRP is involved in the post-translational modifications of a-DG.
The FKRP E310del mice carried a deletion of the C terminus, including the consensus DxD motif, which is thought to be responsible for the glycosyltransferase activity in many enzymes. Genotype analysis reveals that the homozygousnull embryos died before reaching E12.5. Recent reports have also documented that fukutin -null and POMT1 -null embryos did not survive beyond E9.5, suggesting a functional link between these genes (55, 56) . The effects of FKRP on development are likely also mediated by the loss of a-DG glycosylation in the embryos because Dag1 -null embryos displayed gross abnormalities as early as E6.5 (57) . Together, these findings indicate that a complete loss of FKRP protein/ function is incompatible with survival and is in agreement with the observations that no homozygous FKRP -null mutation has ever been identified in humans. Given that both wild-type and truncated E310 FKRP proteins were secreted equally well to the cultured medium when expressed in CHO cells (58), these results suggest that the underlying defects of the E310 deletion were probably due to the loss of an important function associated with the C terminus of FKRP rather than altered trafficking or localization.
In an attempt to modulate the severity and phenotypes of the FKRP mice, we generated compound heterozygous mutations by cross-breeding the heterozygous FKRP-neo-P448/wt mice with the heterozygous E310del/wt mice. Unlike the homozygous FKRP-neo-P448L mice, the number of compound heterozygous FKRP-neo-P448L/E310del mice did not achieve a Mendelian distribution (Table 1 , P448L/E310del). Only a few mutant mice were born and they died at birth. The severe phenotypes were consistent with the observations that the E310 deletion (embryonic lethal) is more deleterious than the P448L missense mutation (viable) when presented in homozygous state. Other lines of evidence also suggest that the severity of disease may be influenced by both the FKRP mutation itself and the level of expression. The expression of FKRP transcripts in both FKRP-neo-P448L and FKRP-Neo Y307N mice is reduced to approximately half of the levels present in the wild-type mice but yet resulting in different degrees of severity (41) . In addition, FKRP expression in mice carrying the homozygous missense L276I mutation (with Neo r cassette) is also decreased by 45%, but the animals do not present any obvious disease phenotypes (Y. Chan, personal observation). In view of these results, it becomes evident that, besides the levels of FKRP expression, the nature of the mutations also plays a critical role in determining the phenotypic variations of different FKRP mutant mouse models. Clinically, L276I and P448L mutations are associated with relatively mild LGMD2I (59) and severe MDC1C phenotypes (28, 36) , respectively. The Y307N mutation is known to cause MEB in human (34, 60) . The correlation between phenotype and genotype in these three lines of mice, therefore, roughly follows a similar trend parallel to patients with the corresponding FKRP mutations.
In this study, we found that the CNS of the mutant FKRP-neo-P448L mice show striking abnormalities reminiscent of some human dystroglycanopathy patients. The primary brain defects include cobblestone (type II) lissencephaly and hydrocephalus. The layering and architecture of both cerebral cortex and cerebellum are highly disorganized and characterized by abnormal neuronal migration. Prominent ocular defects and retinal malformations are also consistent features of the mutant mice. Structural defects of the hippocampus are also observed. Similar pathological features are also shared by other animal models of dystroglycanopathy, including FKRP-Neo Y307N , fukutin chimera, POMGnT1-null, LARGE myd and MORE-DG null mice (19, 41, (52) (53) (54) . Taken together, these results provide strong evidence that proper a-DG glycosylation is essential for corticogenesis and normal eye development. In addition, the pathological similarities also support the argument that FKRP participates with other glycosyltransferases in common pathways involving a-DG modification.
However, the importance of functional glycosylation of a-DG in the pathogenesis of FKRP-related muscular dystrophies is not clearly understood. Previous studies have suggested that the levels of a-DG glycosylation do not always correlate with clinical severity in patients with FKRP and fukutin mutations (39) , and significant amount of functionally glycosylated a-DG can be detected in both LGMD2I and severe MDC1C muscles (39, 40) . To add complexity, a recent study by Ackroyd et al. (41) reported that FKRP-Neo Y307N mice express relatively abundant functional a-DG, but the animals died at or soon after birth. In contrast, functional glycosylation of a-DG is barely detectable in all tissues in the FKRP-neo-P448L mutant mice but some of them have survived more than 10 months, so far. Interestingly, despite the loss of a-DG glycosylation, the heart is spared of pathological changes in the homozygous FKRP-neo-P448L mutant mice and this might contribute to their overall survival. Taken together, these results suggest that FKRP could have other unknown functions and that factors other than glycosylation of a-DG are also important for modulating disease severity. Supporting this view, the expression levels of several proteins known to cause muscular dystrophies were found to differ between the FKRP-neo-P448L mutant mice and other dystroglycanopathy animal models. For example, the levels and staining pattern of a-2 laminin are unaffected in the FKRP-neo-P448L mutant muscles in contrast to the reduced expression reported in the FKRP-Neo Y307N and LARGE myd mice (41, 54) . The levels of several DGC proteins are increased in the skeletal muscles of LARGE myd mice, but not in the FKRP-neo-P448L mutant mice. On the other hand, b 1 -integrin is significantly upregulated in the FKRP-neo-P448L mutant muscles, but its levels are unaffected in the POMGnT1 -null myoblasts (61) . Thus, it is plausible that different secondary pathways may be activated in response to the nature of the mutation, thereby partly contributing to the overall phenotypes in each animal model. Clearly, these observations require further investigation.
In summary, our FKRP knock-in mouse model develops muscle and CNS phenotypes accompanied by severe reduction in functional glycosylation of a-DG and recapitulates the wide clinical spectra associated with FKRP mutations in dystroglycanopathy patients. The FKRP-neo-P448L knock-in mice certainly add to the growing list of animal models for dystroglycanopathies. To the best of our knowledge, our FKRP-neo-P448L mutant mice are the first viable mouse model reported for FKRP-related muscular dystrophies. In the future, it will be possible to generate compound heterozygous mutations of different severity by cross-breeding the FKRP-neo-P448L mice with mice carrying other FKRP mutations. Such animal models will be valuable for dissecting the molecular mechanisms and developing therapies tailored for specific FKRP mutations.
MATERIALS AND METHODS
Generation of FKRP animal models
Knock-in mice were generated by inGenious Targeting Laboratory (Stony Brook, NY, USA). The targeting vector (Fig. 1B) was engineered with a c.1343C.T point mutation, resulting in an amino acid change from proline to leucine at position 448. The Neo r cassette was placed in the intron 2 about 140 bp upstream of the coding exon 3. The construct was designed such that the short homology arm (SA) extends 3 kb away from the Neo r cassette, and the long homology arm (LA) extends 4 kb 3 ′ to the point mutation introduced in exon 3. The targeting vector was electroporated into iTL BA1 (C57BL/6NX129/SvEv) embryonic stem cells, and the correctly targeted ES clones were microinjected into C57BL/6N blastocysts to produce chimeric mice. Germlinetransmitted heterozygous FKRP-neo-P448L/wt mice were obtained by breeding male chimeras with female C57BL/6N mice. FKRP deletion mice were generated using similar approaches by the Animal Models Laboratory at the University of North Carolina, Chapel Hill. The coding region from amino acid E310 to TGA stop codon at position 495 was deleted in the targeting vector, and the Neo r cassette was placed in the 3 ′ UTR region (Fig. 1D) . All mice were housed in the vivarium of Carolinas Medical Center according to animal care guidelines of the institute. All animal studies were approved by the Institutional Animal Care and Use Committee of Carolinas Medical Center.
Genotyping of FKRP mice
Genotypes of the offspring from crossing of heterozygous FKRP-neo-P448L/wt mice were determined by allele-specific PCR using genomic DNA extracted from mouse tails. The primers for amplifying the wild-type allele (Fig. 1A) are 8010 (forward): AGTGGTCTGTTTAGGGCAGG and PT5 (reverse): CCAAACTTCAGCTCCAGGAAG. The primers for amplifying the P448L targeted allele (Fig. 1C) are F3 (forward): GCATAAGCTTGGATCCGTTCTTCGGAC and PT5 (reverse). The primer set A1 (forward): TGAGACGACT GAAGTGGTAACC; UNI (reverse): AGCGCATCGCCTTC TATCGCCTTC was used to confirm the correct integration of the P448L-targeted allele (Fig. 1C) . The following primers were used to determine the genotypes of embryos from crossing of heterozygous E310del/wt mice. Wild-type allele (Fig. 1A) : 4714 (forward): GCTGACAACTTGCTCCA CACTCCC and rN374 (reverse): TTGCCCACGTCCTC CAGGTA. Targeted E310del allele (Fig. 1E) : 4714 (forward), and neo1 (reverse), GAGAACCTGCGTGCAA TCCA. Oligo-primers were synthesized by IDT (Coralville, IA, USA). DNA sequencing was performed on a 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) at the Molecular Core Facility of Carolinas Medical Center.
Southern blot analysis
Secondary confirmation of positive FKRP-neo-P448L embryonic stem cell (ES) clones identified by PCR was performed according to the following procedures. Mouse tail DNA was digested with EcoRV and separated on 0.8% agarose gel. After transfer to a nylon membrane, the digested DNA was hybridized with a 442 bp probe (PB3/4) targeted against the 5 ′ region external to the targeting vector (Fig. 1C) . The probe was amplified by the PCR primers PB3 (forward): ACTGCC TCTACGTAGGCAAAGG and PB4 (reverse): TCCTCTT AGAGGAATGTCTTTGGG. Due to the presence of an additional EcoRV site in the Neo r cassette after homologous recombination, the probe detects a 7.5 kb band for the targeted P448L allele instead of a 12 kb band for the wild-type allele after EcoRV digest.
Quantitative PCR analysis
RNA from quadriceps, gastronemius and heart were isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed with iScript TM cDNA systhesis kit (Bio-Rad, Hercules, CA, USA). Quantitative PCR was performed on an ABI Prism 7500 Fast Real-Time PCR System using TaqMan w Probe-Based Detection (Applied Biosystems). RNA samples were treated with RNase-free DNase before addition of Taqman w gene expression assays and Taqman   w Gene expression master mix. The FKRP probe was custom designed to amplify a 73 bp fragment from exon 3 region. The fukutin (Mm00519882-m2), LARGE (Mm00521885-m1) and DG (Mm00802400-m1) probes were obtained from Applied Biosystems. GAPDH (Mm03302249-g1) was used as an internal control. All reactions were performed in triplicates. Data were analyzed using RealTime StatMiner, version 4.0 (Integromics, Philadelphia, PA, USA). ANOVA was performed whenever multiple factors were involved. Otherwise, t-test was applied.
Histological and morphological analyses
Skeletal muscles and heart were snapped frozen in isopentane chilled with liquid nitrogen. Sections of 6 mm thickness were cut from the frozen tissues and stained with hematoxylin and eosin (H&E), Nissl (cresyl violet) or trichrome. Mouse brains and muscles were fixed in 10% formalin at room temperature for 24 h and then embedded in paraffin. Paraffin blocks are cut into 4 mm serial sections in coronal and sagittal orientation. Images were examined using an Olympus BX51 microscope (Center Valley, PA, USA). Pictures of the whole brain were taken using an Olympus SZ61 stereo microscope. X-ray images of mouse skeleton were taken using a PiXarray 100 Digital Specimen Radiography System (Bioptics, Tucson, AZ, USA).
Electron microscopy
Quadriceps muscle was trimmed into 3 mm blocks and fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in 0.1 M Millonig's phosphate buffer for 30 min at room temperature. Samples were infiltrated with 1% osmic acid, dehydrated in ethanol and then embedded in Spurr resin (Electron Microscopy Sciences). Ultrathin sections on copper grids were stained with 2% uranyl acetate and 0.3 M lead citrate and analyzed with a Philips CM-10 Transmission Electron Microscope operated at 60 kV. Digital images were captured with a digital camera system from 4pi Analysis (Durham, NC, USA).
Statistical analysis
Descriptive statistics including means and standard deviations, or counts and percentages were calculated for body weight and serum blood tests. For data measured on the interval scale, analysis of variance (ANOVA) was used, followed by Turkey's test where appropriate. If the data were not normally distributed, the Kruskal-Wallis test or Wilcoxon's rank sum test was employed. The SAS w , version 9.1, was used for all analyses. A two-tailed P-value of ,0.05 was considered statistically significant.
Antibodies
Antibodies used in the study were listed in Supplementary Material, Table S1 .
Immunofluorescent analysis
Frozen cross-sections of muscles were cut at a thickness of 6 mm and blocked with 10% normal goat serum and 20% fetal bovine serum diluted in phosphate-buffered saline (PBS) for 30 min. Sections were incubated at room temperature with the primary antibodies, IIH6C4 (1:200, overnight at 48C), laminin a2 (1:200, 1 h), DAG-1 (1:2000, 1 h) and dystrophin P7 (1:500, 1 h). All antibodies were diluted in PBS containing 10% fetal bovine serum. Sections were rinsed extensively with PBS and then incubated with AlexaFluor 594-conjugated anti-mouse or anti-rabbit secondary antibodies (Molecular Probes/Invitrogen). Sections were also stained with secondary antibody as negative controls. Immunofluorescence was visualized using an Olympus BX51 fluorescent microscopy. Images were captured using an Olympus DP70 CCD camera system at standard gain and at same exposure time.
Protein extraction and western blot analysis
Total proteins were extracted from tissues of interest using TX-100 buffer (1% Triton X-100, 50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS) supplemented with protease inhibitor cocktail (Roche, Germany). Tissues were homogenized in TX-100 buffer and the supernatants were collected by centrifugation at 18 000g for 15 min. The lysates were then passed through Zeba desalting column (Pierce, Rockford, IL, USA) and loaded on 4 -20% Tris-glycine gel (Invitrogen). Protein concentration was determined by modified Lowry assay (Bio-Rad DC protein assay). For western blot, polyvinylidene difluoride (PVDF) membranes were incubated with protein-free T20-blocking buffer (Pierce, Rockford, IL, USA). Primary and secondary antibodies were incubated in 20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20 and 0.5% gelatin at recommended concentrations (Supplementary Material, Table S1 ). Blots were developed with ECL (PerkinElmer, Waltham, MA, USA) and the images were exposed and processed by an LAS-4000 imaging system (Fujifilm, Valhalla, NY, USA).
Laminin-binding assay
Proteins were transferred to PVDF membranes and incubated for 6 h at 48C in laminin overlay buffer (10 mM ethanolamine, 140 mM NaCl, 1 mM MgCl 2 and 1 mM CaCl 2 , pH 7.4) containing 5% nonfat dry milk. Laminin probe was prepared by conjugating Engelbreth-Holm-Swarm laminin (Sigma, St. Louis, MO, USA) with EZ-link plus activated horseradish peroxidase (HRP) according to manufacturer's protocol (Pierce). The activated laminin probe was desalted with Micro Bio-Spin P-30 column (Bio-Rad). Membranes were incubated with the labeled laminin -HRP (5 mg/ml) overnight at 48C. After washing extensively with laminin overlay buffer containing 5% nonfat dry milk, blots were developed with ECL.
